Partnerships, Product Recall, New Contracts, Promotions, and Stock Movement - Research Report on Valeant, CareFusion, Envision Healthcare, Seattle Genetics, and Osiris

NEW YORK, October 7, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Valeant Pharmaceuticals International, Inc. (NYSE: VRX), CareFusion Corporation (NYSE: CFN), Envision Healthcare Holdings Inc. (NYSE: EVHC), Seattle Genetics, Inc. (NASDAQ: SGEN), and Osiris Therapeutics, Inc. (NASDAQ: OSIR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Valeant Pharmaceuticals International, Inc. Research Report

On October 2, 2013, Valeant Pharmaceuticals International, Inc. (Valeant) announced a partnership with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. The Company reported that it has pledged to donate a portion of sales from all Medicis and Obagi products to the NCADV in support of its initiatives. J. Michael Pearson, Chairman and CEO of Valeant said, "This partnership provides a platform for us to partner with all stakeholders in the industry, from our employees to the medical community to the consumers who use our products, in the battle to end domestic violence. We are excited about the long-term prospects to improve the lives of women through this initiative." The Full Research Report on Valeant Pharmaceuticals International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9fdd_VRX]

--

CareFusion Corporation Research Report

On September 30, 2013, CareFusion Corporation (CareFusion) announced an update regarding its previously announced voluntary recall of AVEA ventilators, which was initiated on September 3, 2013. The Company informed that the Food and Drug Administration (FDA) classified this action as a Class I recall, which is defined as a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The Company further stated that while all AVEA ventilators fall under the voluntary recall, hospitals in locations at high elevations (higher than 5,000 feet above sea level) that are using the AVEA ventilator in the neonatal patient care setting are at greatest risk of this error. The Company added that it has received five complaints from a facility that was operating in the neonatal patient care settings and was located higher than 5,000 feet above sea level. CareFusion, however, maintained that no injuries have been directly attributed to the issue. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4933_CFN]

--

Envision Healthcare Holdings Inc. Research Report

On October 1, 2013, Envision Healthcare Holdings Inc. (Envision Healthcare) announced that American Medical Response (AMR), its subsidiary, expects the beginning of three new contracts will add approximately 205,000 transports a year to its total. AMR reported that on November 1, 2013, it will begin providing 911 emergency transportation services to residents of Tulsa, Oklahoma City and surrounding cities under a new contract with Oklahoma's Medical Services Authority. The five-year contract is estimated to generate revenue of $247 million over the five-year period. AMR further informed that it recently began providing 911 emergency transportation services under multi-year contracts to both DeKalb County, Georgia, and Shelby County, Tennessee. AMR reported that the two contracts have annual estimated revenue of $23 million, and will serve approximately 350,000 residents. AMR President Edward Van Horne, said, "We are very proud to have won these contracts and to be the emergency medical services provider of choice in these communities. AMR is the country's leading 911 emergency medical services company because of the exceptional customer and clinical services we provide to our community partners." The Full Research Report on Envision Healthcare Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4b31_EVHC]

--

Seattle Genetics, Inc. Research Report

On October 2, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced the promotion of Jonathan Drachman, M.D., to Chief Medical Officer and Executive Vice President, Research and Development. In this role, he will be responsible to lead the Company's clinical development and regulatory affairs teams, in addition to his continued oversight of research and translational medicine. The Company also announced the promotion of Eric Sievers, M.D., to Senior Vice President, Clinical Development. Seattle Genetics stated that in this role, Dr. Sievers will be responsible for clinical development and life cycle management activities for ADCETRIS (brentuximab vedotin). The Full Research Report on Seattle Genetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ff98_SGEN]

--

Osiris Therapeutics, Inc. Research Report

On October 2, 2013, Osiris Therapeutics, Inc.'s (Osiris) stock rose sharply by 12.37%, ending the day at $18.80. Over the previous three trading sessions, shares of Osiris gained 13.32%, outperforming the Nasdaq Composite, which gained 0.88% during the same period. The Full Research Report on Osiris Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/82ba_OSIR]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner